JQKD82 HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 408145

CAS#: 2410512-38-6 (free base)

Description: JQKD82, also known as PCK82, is a cell-permeable and selective KDM5 inhibitor (MM.1S cells, IC50 = 0.42 uM). JQKD82 increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. JQKD82 is a useful tool compound to block KDM5A function as a potential therapeutic strategy for MM. QKD82 is a more stable ester of KDM5-C49 that is able to deliver the active molecule KDM5-C49 to cells more efficiently


Chemical Structure

img
JQKD82 HCl
CAS# 2410512-38-6 (free base)

Theoretical Analysis

MedKoo Cat#: 408145
Name: JQKD82 HCl
CAS#: 2410512-38-6 (free base)
Chemical Formula: C27H43Cl3N4O5
Exact Mass: 500.2999
Molecular Weight: 610.01
Elemental Analysis: C, 53.16; H, 7.11; Cl, 17.43; N, 9.18; O, 13.11

Price and Availability

Size Price Availability Quantity
1.0mg USD 150.0 Ready to ship
5.0mg USD 550.0 Ready to ship
10.0mg USD 950.0 Ready to ship
25.0mg USD 1650.0 Ready to ship
50.0mg USD 2950.0 Ready to ship
100.0mg USD 4950.0 Ready to ship
Bulk inquiry

Related CAS #: 2410512-38-6 (free base)    

Synonym: JQKD82 HCl; JQKD82 hydrochloride; JQKD82; JQKD-82; JQKD 82; PCK82; PCK-82; PCK 82;

IUPAC/Chemical Name: 2,4-diisopropoxyphenyl 2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl)isonicotinate trihydrochloride

InChi Key: VSTHCFWHQMJPDZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H40N4O5.3ClH/c1-8-31(14-13-30(6)7)26(32)18-28-17-22-15-21(11-12-29-22)27(33)36-24-10-9-23(34-19(2)3)16-25(24)35-20(4)5;;;/h9-12,15-16,19-20,28H,8,13-14,17-18H2,1-7H3;3*1H

SMILES Code: O=C(OC1=CC=C(OC(C)C)C=C1OC(C)C)C2=CC=NC(CNCC(N(CCN(C)C)CC)=O)=C2.[H]Cl.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: KDM5 inhibitor (MM.1S cells, IC50 = 0.42 uM)
In vitro activity: JQKD82 inhibited the growth of MM.1S cells in a dose and time-dependent manner (Supplementary Fig. S3A). JQKD82 was 7-fold more potent than KDM5-C70, and more than 20-fold more potent than KDM5-C49 at eliciting growth suppression in MM.1S cells (JQKD82 IC50 = 0.42 M, KDM5-C49 IC50 > 10 M, KDM5-C70 IC50 = 3.1 M) (Fig. 3A). Further, JQKD82 treatment resulted in suppressed growth in a panel of MM cell lines (Fig. 3B). These results were validated by treatment of five primary MM patient samples with JQKD82, which demonstrated a 40-50% reduction in cell viability after five days of treatment (Fig. 3C). As a control, we isolated normal B cells from healthy individuals, and treated these cells with JQKD82. CD40 antibody and IL-4-stimulated B cells were insensitive to the effects of JQKD82 (Fig. 3D), indicating that KDM5 inhibition may have a favorable in vivo therapeutic index. To further establish whether JQKD82 was effective at suppressing growth across multiple distinct lineages, we performed a screen of 367 distinct cancer cell lines, which were barcoded and pooled (39). JQKD82 was effective at reducing the growth of multiple tumor cell lineages, including MM cells, indicating potential cross-cancer utility (Supplementary Fig. S3B).
In vivo activity: JQKD82 results in a dramatic reduction of MYC immunostaining in vivo (Fig 3K). In parallel to this, two groups of mice were treated with either JQKD82 or vehicle (n = 10 for each group) once tumor engraftment was confirmed by sequential BLI. As in our intravenous model, JQKD82 treatment for 14 days also significantly inhibited tumor growth, evidenced both by BLI and tumor size measurement (Supplementary Fig. S3H and S3I). These results indicate that JQKD82 is effective and well tolerated in vivo in two models of MM, and suggests a link between KDM5 function and MYC expression.

Preparing Stock Solutions

The following data is based on the product molecular weight 610.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma Hiroto Ohguchi1*#, Paul M.C. Park2*, Tingjian Wang2*, Berkley E. Gryder3,4*, Daisuke Ogiya5, Keiji Kurata5, Xiaofeng Zhang2, Deyao Li2, Chengkui Pei2, Takeshi Masuda6, Catrine Johansson7, Virangika K. Wimalasena2, Yong Kim3, Shinjiro Hino8, Shingo Usuki9, Yawara Kawano10, Mehmet K. Samur5, Yu-Tzu Tai5, Nikhil C. Munshi5, Masao Matsuoka10, Sumio Ohtsuki6, Mitsuyoshi Nakao8, Takashi Minami11, Shannon Lauberth12, Javed Khan3, Udo Oppermann7,13, Adam D. Durbin14, Kenneth C. Anderson5,15#, Teru Hideshima5#, Jun Qi2,15,16#